Possessing an apolipoprotein E (APOE) e4 allele, advanced age and smoking are risk factors for Alzheimer's disease and cognitive decline. Deficits in cognitive function also increase risk for smoking relapse. Data from 917 adult smokers of European ancestry were pooled across three randomized trials of smoking cessation. We examined whether smokers who carry at least one e4 allele (n ¼ 252) have more difficulty quitting smoking compared with noncarriers (n ¼ 665), and whether age moderated this association. The genotype by age interaction was significant for 7-day point-prevalence abstinence rates (P ¼ 0.04) and time to 7-day failure (P ¼ 0.03). Among smokers over age 60, e4 carriers were less likely to quit (odds ratio ¼ 0.27, P ¼ 0.018) and relapsed more quickly (hazard ratio ¼ 3.38, P ¼ 0.001) compared with noncarriers. The genotype association with relapse was nonsignificant among younger smokers. An increased understanding of the underlying pathophysiological mechanisms of this association could facilitate the development of targeted therapies for smokers with increased risk for cognitive decline.
INTRODUCTION
Chronic nicotine exposure produces neuroadaptive changes that make quitting smoking difficult.
1,2 Persistent smoking is motivated in part by the positive rewarding effects of acute nicotine delivery, including cognitive-enhancing effects. 2, 3 In contrast, quitting smoking produces deficits in executive cognitive function. 4 These deficits encompass a broad range of cognitive processes in both animals and humans, including deficits in attention, 5, 6 learning, 7,8 memory 9-12 and behavioral control. 13, 14 Importantly, deficits in executive cognitive function have an important role in smoking relapse in the general population of smokers 15, 16 as well as clinical populations. 17, 18 Evidence linking cognitive function and smoking relapse risk suggests that smokers who are susceptible to cognitive impairment may have greater difficulty quitting smoking. 19 Although not yet studied as a smoking relapse susceptibility gene, a relatively common variant in the apolipoprotein E (APOE) gene, widely studied for its role in cognitive aging, would be a plausible risk marker. The functional APOE e4 allele is associated with increased risk of developing Alzheimer's disease, with a 2-to 3-fold increase for e4 heterozygotes and 12-to 14-fold increase for e4 homozygotes. 20 Before the emergence of clinical symptoms of Alzheimer's disease, healthy e4 carriers exhibit deficits in executive cognitive function, memory and perceptual speed that are qualitatively similar to those experienced by abstinent smokers. [21] [22] [23] Compared with noncarriers, healthy e4 carriers also exhibit changes in brain structure [24] [25] [26] and function [27] [28] [29] that may reduce cognitive control over behaviors such as smoking. Thus, it is plausible that otherwise healthy e4 carriers may be prone to 'self-medicate' cognitive symptoms by smoking. 30 Converging lines of evidence for nicotine's pro-cognitive effects, the role of cognitive deficits in smoking relapse and the presence of cognitive deficits in healthy APOE e4 allele carriers suggest the hypothesis that the APOE genotype may influence the ability to quit smoking. We tested this hypothesis in a sample of 917 smokers who participated in three independent smoking cessation clinical trials: a randomized placebo-controlled trial of bupropion, a randomized open-label trial of nicotine patch vs nicotine spray and an open-label trial of nicotine patch. 31, 32 We predicted that smokers with at least one e4 allele would have reduced abstinence rates and shorter time to relapse. Based on evidence that the deleterious effects of the e4 allele on cognition in healthy carriers tend to become more pronounced with advancing age, 33 age was tested as a moderator of genetic associations. Thus, we predicted that older e4 carriers would be at the greatest risk for relapse. An understanding of the relationship of the APOE e4 allele to smoking relapse could advance our understanding of underlying neurobiological mechanisms and point to novel therapeutic targets for medications development.
MATERIALS AND METHODS
Data from participants (n ¼ 917) across the independent clinical trials were pooled for analysis. The three trials were comparable with respect to the ascertainment methods, eligibility criteria and study procedures. The analyses were limited to smokers of European ancestry; prior analyses of ancestry informative markers in these trials revealed no evidence for significant ethnic admixture that could bias genetic association analyses. 32, 34, 35 Participants and procedures (study 1; bupropion placebo-controlled trial) Treatment-seeking smokers responding to advertisements were screened for eligibility from April 1999 to October 2001 at Georgetown University 1 (Washington, DC, USA) and SUNY (Buffalo, NY, USA). Inclusion criteria were: ages 18-65 and a smoking rate of 410 cigarettes a day for the previous 12 months. As is often the convention in phase III pharmacotherapy trials in nicotine dependence, individuals with comorbid diagnoses were excluded because of safety concerns and interacting psychoactive medications. Specifically, we excluded for a history of Diagnostic and Statistical Manual of Mental Disorders, 4th Edition axis I psychiatric disorders (except nicotine dependence), seizure disorder, current use of psychotropic medications, and pregnancy or lactation. There were 555 participants included in the intent-to-treat analysis, including 436 of self-reported European ancestry. Of the 404 participants for which DNA was available, APOE genotyping was completed for 383 participants (failed single-nucleotide polymorphism (SNP) assays and DNA samples with low call rates were removed from the data set after confirming replicate concordance). Of the 383 eligible participants, 55% were female, 47% were college graduates, the average age was 44 Figure 1A) .
The study was approved by the institutional review boards from both universities (Clinicaltrials.gov registration number NCT00322205). Participants at both sites received identical assessments of demographics, smoking rate and nicotine dependence (FTND), 36 and provided a 40-ml blood sample for genotyping. In this double-blind placebo-controlled study, participants were randomized to receive 10 weeks of bupropion or matched placebo. Bupropion was administered according to the standard dosing regimen (150 mg day À 1 for the first 3 days, followed by 300 mg day À 1 ). Participants were instructed to quit on a target quit date 2 weeks after initiating treatment. All participants received seven sessions of standardized cessation counseling during the medication phase. Selfreported smoking was assessed using the time-line follow-back procedure. 37 The primary outcome was biochemically verified (saliva cotinine p15 ng ml À 1 ) 7-day point-prevalence abstinence at the end of treatment and 6-month post-target quit date.
Participants and procedures (study 2; transdermal nicotine therapy open-label trial)
Treatment-seeking smokers were screened at the University of Pennsylvania (Philadelphia, PA, USA) from 2004 to 2008, using methods and inclusion criteria similar to those described above. In the full cohort of 568 trial participants, there were 478 smokers of self-reported European ancestry. Of these, DNA was available for 443 participants and APOE genotyping was completed for 418 (failed SNP assays and DNA samples with low call rates were removed from the data set after confirming replicate concordance). Of the 418 eligible participants, 42% were female, 35% were college graduates, the average age was 45.2 (s.d. ¼ 10.5) years and baseline depression scores were 8.5 (s.d. ¼ 6.6). On average, participants smoked 22 cigarettes per day (s.d. ¼ 8.9) and were moderately nicotine dependent (mean FTND ¼ 5.3; s.d. ¼ 2.2). In total, 204 (49%) participants were randomized to the extended nicotine patch condition, and 214 (51%) to the standard nicotine patch condition (Supplementary Figure 1B) .
The study protocol was approved by the University of Pennsylvania institutional review board (Clinicaltrials.gov registration number NCT00364156). Participants completed pre-treatment assessments identical to those described above. After a pre-quit counseling session, transdermal nicotine-patch therapy was initiated on the target quit date and continued for 8 weeks. For the following 16 weeks, those in the extended treatment condition continued using nicotine patches while those in the standard treatment condition were given placebo patches. All participants received three sessions of behavioral counseling during the treatment period. The primary outcome was 7-day point-prevalence abstinence at the end of 8-week treatment (end of treatment) and at 6-month follow-up. Self-reported smoking for the 7 days before each follow-up survey was biochemically verified using exhaled breath carbon monoxide.
Participants and procedures (study 3; nicotine replacement therapy open-label trial (patch vs spray)) Treatment-seeking smokers were recruited at Georgetown University and the University of Pennsylvania, from February 2000 to August 2003, using methods and inclusion criteria similar to those described above. In the full cohort of 600 participants, there were 397 smokers of self-reported European ancestry. Of these, DNA was available for 191 participants and APOE genotyping was completed for 116 participants (failed SNP assays and DNA samples with low call rates were removed from the data set after confirming replicate concordance). Of the 116 eligible participants, 43% were female, 61% were college graduates, the average age was 46 Figure 1C) .
The study was approved by the institutional review boards from both universities (Clinicaltrials.gov registration number NCT00326781). The procedures and outcome assessments were identical to those described above, except that participants were randomized to nicotine patch or nicotine nasal spray. Abstinence criteria were identical to those described above.
Measures
Genotyping. APOE e2, e3 and e4 alleles were determined from allelic variants of two SNPs (NCBI SNPs rs429358 and rs7412), which are differentiated on the basis of an amino-acid substitution at positions 112 and 158. The e2 allele is characterized based on the presence of cysteine at both sites, the e3 allele has cysteine at site 112 and arginine at site 158, and the e4 allele has arginine at both sites. 38 Genotyping was completed using the ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA). PCR was performed with 2.25 ng of DNA, 2.5 ml of ABI Taqman Universal Mastermix, 0.125 ml of water and 0.125 ml of 40X Assay on Demand SNP Assay for the APOE variant (ABI, Foster City, CA, USA). The 5-ml reactions were performed in a 384-well plate (ABI). The plates were scanned utilizing the Allelic Discrimination End-Point Analysis on the ABI Prism 7900HT Sequence Detection System. The allelic discrimination data were analyzed by the AutoCall algorithm of the SDS v2.1 Software (ABI).
Covariates. Sex, education, age and nicotine dependence (FTND) 36 were assessed at baseline. The Center for Epidemiological Studies Depression measure 39 was used to assess baseline depression symptoms.
Outcomes. In accordance with the guidelines of the Society for Research on Nicotine and Tobacco, 40 we examined 7-day point-prevalence abstinence (end of treatment and 6 months), defined as self-reported abstinence (not even a puff) for each of the 7 days immediately before the follow-up point and biochemically verified by a cotinine reading of p15 ng ml À 1 (study 1) or a carbon monoxide reading of p10 p.p.m. (studies 2 and 3). Consistent with these recommendations, participants who failed to provide a sample for biochemical verification, or those exceeding the detection threshold, were coded as non-abstinent. Time to 7-day failure censored at 6 months was also examined. Relapse was defined as 7 or more consecutive days of smoking, and considered to have occurred on the first day of the smoking interval. 40 Participants lost to follow-up were considered to be smokers, and time of relapse was recorded as the time of last contact.
Exploratory outcome. Self-reported inattention symptoms 41 were assessed at baseline in all three trials, and on the target quit date in the bupropion trial and the nicotine replacement therapy (NRT; patch vs spray) trial. This measure was used as a proxy for cognitive deficits, based on evidence that smokers with inattention symptoms are more likely to 'selfmedicate' with nicotine. 42 Statistical analysis. Preliminary analyses were conducted to examine differences between e4 carriers and noncarriers on baseline demographic and smoking characteristics using w 2 or one-way analysis of variance. As data were pooled across studies, treatment arm was controlled for in all models. The primary outcome, point-prevalence abstinence, was analyzed by longitudinal logistic regression, estimated using generalized estimating equation methods. APOE e4 carrier status was dichotomized as at least one e4 allele (e4 carrier) vs no e4 alleles (e4 noncarrier). As advanced age is a risk factor for cognitive decline, models were constructed that examine its effects independently and combined with APOE on the primary and secondary outcomes. Thus, the model included APOE e4 carrier status (e4 noncarrier ¼ 0, e4 carrier ¼ 1), age, treatment arm, timepoint and the genotype Â age interaction. The treatment arm Â timepoint and genotype Â treatment arm interactions were not included because they were not significant and did not alter the genotype by age interaction. Sex, nicotine dependence, education and baseline depression were included as covariates. Cox regression models were used to analyze time to 7-day failure. To illustrate the genotype by age interaction, the data were stratified into five age groups and the genotype effect was tested within each age group. To test whether e4 carriers and noncarriers differed at baseline in terms of cognitive deficits, linear regression models were used to test for the presence of a genotype by age interaction on baseline inattention symptoms in the pooled sample. A similar regression model tested age by genotype effects on inattention symptoms reported on the target quit date in the bupropion trial and the NRT open-label trial, controlling for baseline inattention symptoms. Both models included the covariates described above. An adjusted P-value of 0.038 was used to account for testing two outcomes with a correlation of r ¼ 0.61. All analyses were conducted using STATA 12.0 (Stata, College Station, TX, USA).
RESULTS

Participant characteristics
In the pooled sample (N ¼ 917), there were 9 (1%) e2/e2, 100 (11%) e2/e3, 24 (2.6%) e2/e4, 556 (60.6%) e3/e3, 214 (23.3%) e3/e4 and 14 (1.5%) e4/e4. APOE genotypes were in Hardy-Weinberg equilibrium for the pooled sample (P ¼ 0.14), and for the three individual clinical trials (all P-values 40.10). Across the three trials, e4 carrier status did not differ between those who received placebo compared with active treatment (P ¼ 0.65). Table 1 depicts the descriptive data by APOE e4 carrier status (e4 À (n ¼ 665) vs e4 þ (n ¼ 252)) for the pooled sample. There were no genotype differences within each of the five age categories for tobacco use characteristics or demographics (P-values40.09).
Abstinence Overall, 275 (30%) participants met criteria for 7-day pointprevalence abstinence at end of treatment and 223 (24.3%) were abstinent at 6 months. Using an adjusted P-value (P ¼ 0.038), there was a marginal genotype by age interaction, independent of treatment arm and follow-up time point, for quit rates (odds ratio (OR) ¼ 0.972, 95% confidence interval (CI) ¼ 0.946-0.999, P ¼ 0.04) and a significant interaction for time to 7-day failure (hazard ratio (HR) ¼ 1.02, 95% CI ¼ 1.002-1.04, P ¼ 0.029). To illustrate the interacting effects of genotype and age on quit rates, the data were stratified into five age categories (18-30, 31-40, 41-50, 51-60 and over 60 years) and the genotype effect was tested within each age group. In the oldest age group, e4 carriers were significantly less likely to quit (OR ¼ 0.27, 95% CI ¼ 0.092-0.798, P ¼ 0.018; Figure 1 ) and have shorter time to relapse (HR ¼ 3.38, 95% CI ¼ 1.62-7.05, P ¼ 0.001; Figure 2 ) compared with e4 noncarriers. There were no significant genotype effects in other age groups (P-values40.05). Education was not significantly related to either outcome (P-values40.33). The pattern of results in the NRT trials and the bupropion trial were very similar (Figure 3 ).
Inattention symptoms Genotype groups were comparable at baseline with respect to inattention symptoms (P-values40.4). However, a significant genotype by age interaction was observed on the target quit date in the placebo group (P ¼ 0.046). Controlling for baseline symptoms, older e4 carriers reported significantly more inattention symptoms at target quit date compared with older e4 noncarriers (P ¼ 0.044). In contrast, younger e4 carriers did not differ from younger e4 noncarriers (P ¼ 0.29). There were no genotype effects in the groups receiving active treatment with bupropion or NRT (P-values40.25).
DISCUSSION
In this sample of treatment-seeking smokers, APOE gene variation was associated with the ability to quit smoking and time to relapse in an age-dependent manner. Among older smokers, APOE e4 carriers had a significantly increased risk of relapse and relapsed more quickly. To our knowledge, this is the first study to examine the relationship of APOE genotype with smoking relapse.
There are a number of plausible neurobehavioral mechanisms that may explain these findings. Binding to neuronal nicotinic acetylcholine receptors, nicotine enhances cholinergic signaling and synaptic plasticity, effects thought to contribute to its cognitive-enhancing effects. 1, 43 Effects of acute nicotine delivery may be particularly rewarding for older APOE e4 carriers given their susceptibility to cognitive deficits. 22, 23, 44, 45 Supporting this hypothesis, data from a recent placebo-controlled trial show that a low dose of transdermal nicotine improves executive cognitive function in non-smoking individuals with mild cognitive impairment, an effect that appears more pronounced among e4 carriers. 46 It should be noted, however, that we did not observe genotype differences in cognitive symptoms of inattention at baseline, although this may be attributable to the fact that all participants were smoking at that assessment. Alternatively, it is possible that older APOE e4 carriers experience more profound withdrawal-related cognitive deficits than noncarriers, an effect that could increase smoking relapse risk. 15, 18, 42 Although the clinical trials reported here did not include objective cognitive assessments, we conducted exploratory analyses of self-reported cognitive symptoms of inattention 41 on the target quit date within the bupropion and open-label NRT trials for which target quit date measures were available. Among smokers receiving placebo within the bupropion trial, there was a genotype by age interaction suggesting that older (unmediated) e4 carriers reported more inattention symptoms on the target quit date compared with older e4 noncarriers, controlling for baseline symptoms. No such interactions were observed among smokers receiving active treatment in these trials.
It is also possible that smokers carrying an APOE e4 allele have limitations in cognitive resources that are essential to exert behavioral control over cravings and impulses to smoke. For example, relative to noncarriers, healthy e4 carriers exhibit alterations in neural activation in the prefrontal cortices while performing cognitive tasks, 21, 47 as well as decreases in functional connectivity. 25 Age-related cortical thinning observed among e4 carriers 26 may also contribute to a reduction in cognitive control resources required to maintain smoking abstinence. Interestingly, these alterations in cognition and brain function are qualitatively similar to those observed in abstaining smokers. [48] [49] [50] [51] Although these findings were observed in a large sample of treatment-seeking smokers, there are some limitations of this work. Although we controlled for education level, we did not screen for dementia, which may be important factors to consider. Using inattention symptoms as a proxy for cognitive impairment, we did not observe differences between e4 carriers and e4 noncarriers at baseline, but it is possible that smoking masked these differences. In addition, although our sample ranged in age from 19 to 82 years old, the majority of participants were between the ages of 40 and 60. Thus, more work needs to be done to examine smoking cessation rates in younger and older e4 carriers. Further, we included only smokers of European ancestry, and prior analyses of trial participants provide no evidence for ethnic admixture using ancestry informative markers. 32, 34, 35 A strength of our study is the relatively large sample size, but the generalizability of these findings to smokers with different ethnic backgrounds should be examined in future studies. Although the three clinical trials reported here were designed as pharmacogenomic trials and DNA was collected from all participants, the present analyses were post hoc. Independent validation in prospective clinical trials will be key to establish the translational significance of the current findings.
Conclusions and directions for future research Although the neurobiological mechanisms of this association remain to be elucidated, these findings may have implications for preventive neurology. For example, smokers known to carry an e4 allele may be aided in their quitting attempts with cholinergic medications such as cholinesterase inhibitors, 52, 53 and/or with nonpharmacological approaches such as cognitive exercise training. 54 Given the detrimental effects of continued smoking on risk for tobacco-related illness as well as risk of cognitive decline, such efforts could have substantial clinical significance.
CONFLICT OF INTEREST
Dr Lerman has served as a consultant and/or has received research funding from GlaxoSmithKline, AstraZeneca, Novartis and Pfizer. The current study was not supported by industry funds. Dr Wileyto has served as a consultant for Pfizer. The remaining authors declare no conflict of interest.
